Department of Neurosurgery, University of Texas MD Anderson Cancer Center, 6767 Bertner Ave, Houston, Texas 77030. United States.
Curr Pharm Des. 2017 Nov 16;23(29):4290-4302. doi: 10.2174/1381612823666170710144325.
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults with intensive heterogeneity and one of the most lethal human cancers. Protein kinases control diverse cellular processes by coordinating different signaling pathways. Protein kinases are frequently dysregulated in human cancers, which contributes to tumor initiation and development. Thus, protein kinases are a growing drug target class for cancers including glioblastoma. This review focuses on the most important protein kinases and kinase-mediated signaling cascades in glioblastoma, and discusses the functional mechanism of these kinases in glioblastoma tumorigenesis. Moreover, this review has summarized the most recent preclinical and clinical advances of agents targeting protein kinases in the treatment of glioblastoma.
多形性胶质母细胞瘤（GBM）是成人中最常见的恶性原发性脑肿瘤，具有强烈的异质性，是人类最致命的癌症之一。蛋白激酶通过协调不同的信号通路来控制多种细胞过程。蛋白激酶在人类癌症中经常失调，这有助于肿瘤的发生和发展。因此，蛋白激酶是包括胶质母细胞瘤在内的癌症的一个不断发展的药物靶点类别。本综述重点介绍了胶质母细胞瘤中最重要的蛋白激酶和激酶介导的信号级联，讨论了这些激酶在胶质母细胞瘤肿瘤发生中的功能机制。此外，本综述总结了靶向蛋白激酶治疗胶质母细胞瘤的最新临床前和临床进展。
